Ramucirumab information

Ramucirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	VEGFR2 (KDR)
Clinical data
Trade names	Cyramza
Other names	LY3009806, IMC-1121B
AHFS/Drugs.com	cyramza
Routes of; administration	Intravenous infusion
ATC code	L01FG02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Metabolism	Probably proteases
Elimination half-life	14 days
Identifiers
CAS Number	947687-13-0 ;
DrugBank	DB05578 ;
ChemSpider	none;
UNII	D99YVK4L0X;
Chemical and physical data
Formula	C6374H9864N1692O1996S46
Molar mass	143609.63 g·mol−1
	(what is this?) (verify)

Ramucirumab^[3] (brand name Cyramza^[4]^[5]) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab, American Medical Association.
^ "FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer". FierceBiotech. 21 April 2014.
^ "Cyramza official website".

[1] "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[2] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[3] Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab, American Medical Association.

[4] "FDA OKs Lilly's blockbuster hopeful ramucirumab for stomach cancer". FierceBiotech. 21 April 2014.

[5] "Cyramza official website".

Ramucirumab information

and 27 Related for: Ramucirumab information

Ramucirumab

Insulin

Dehydroepiandrosterone

Lung cancer

Dexamethasone

Scripps Research

Monoclonal antibody therapy

Trastuzumab deruxtecan

Cerebrolysin

Bevacizumab

ImClone Systems

Osimertinib

Fruquintinib

Erythropoietin

Lenvatinib

Tyrosine kinase inhibitor

Dasatinib

HER2

Merestinib

Trastuzumab emtansine

Erlotinib

Integrin

Thrombopoietin

Cabozantinib

Wnt signaling pathway

Basic fibroblast growth factor

Ponatinib